Hollis-Eden Pharmaceuticals (HEPH) rose after it presented positive data from an animal trial on an experimental drug for rheumatoid arthritis.
The new synthetic steroid hormone, HE3286, showed a dramatic benefit in rodents with collagen-induced arthritis when compared with a placebo, reducing the severity of the disease. Shares were up 4.1% to $5.56.
The company raised its earnings prediction to at least $2.05 a share, before items, from the prior estimate of about $2. Pfizer attributed the revised outlook to a "favorable trend in revenues and lower costs" in the fourth quarter. On average, analysts polled by Thomson First Call had forecast $2.02, excluding one-time items. Shares of Pfizer were up 2% to $27.62.Cadence Pharmaceuticals (CADX) reported a wider loss in the most recent quarter as expenses became more cumbersome. The company lost $7.8 million, or $6.01 a share, in the latest quarter, compared with a loss of $2.4 million, or $2.04 a share, a year ago. Operating expenses in the quarter were $8 million, more than three times last year, primarily because of costs related to an ongoing phase III trial of Omigard. Shares of Cadence, which completed its initial public offering last month, were unchanged at $12.